Healthcare provider profile · identity verified

Peter John Weigel, M.D.

Internal Medicine · WESTFIELD, NJ · NPI 1043272768

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	497	141
Atorvastatin Calcium	Atorvastatin Calcium	495	150
Levothyroxine Sodium	Levothyroxine Sodium	416	110
Lisinopril	Lisinopril	366	111
Losartan Potassium	Losartan Potassium	352	102
Metformin Hcl	Metformin Hcl	254	83
Tamsulosin Hcl	Tamsulosin Hcl	239	70
Rosuvastatin Calcium	Rosuvastatin Calcium	231	75
Pantoprazole Sodium	Pantoprazole Sodium	201	64
Metoprolol Succinate	Metoprolol Succinate	193	61
Simvastatin	Simvastatin	177	42
Hydrochlorothiazide	Hydrochlorothiazide	176	58
Omeprazole	Omeprazole	175	57
Allopurinol	Allopurinol	159	42
Gabapentin	Gabapentin	141	34
Tramadol Hcl	Tramadol Hcl	140	28
Metoprolol Tartrate	Metoprolol Tartrate	133	32
Trazodone Hcl	Trazodone Hcl	133	31
Furosemide	Furosemide	115	34
Eliquis	Apixaban	111	29
Zolpidem Tartrate	Zolpidem Tartrate	107	21
Alprazolam	Alprazolam	99	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	97	26
Glimepiride	Glimepiride	91	26
Escitalopram Oxalate	Escitalopram Oxalate	90	30
Sertraline Hcl	Sertraline Hcl	89	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	80	21
Pravastatin Sodium	Pravastatin Sodium	76	22
Albuterol Sulfate Hfa	Albuterol Sulfate	73	37
Bupropion Xl	Bupropion Hcl	68	15
Duloxetine Hcl	Duloxetine Hcl	68	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	66	15
Lorazepam	Lorazepam	66	12
Warfarin Sodium	Warfarin Sodium	66	15
Clopidogrel	Clopidogrel Bisulfate	62	19
Pregabalin	Pregabalin	60	14
Meloxicam	Meloxicam	55	14
Oxycodone Hcl	Oxycodone Hcl	53	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	suppressed
Ropinirole Hcl	Ropinirole Hcl	52	suppressed
Jardiance	Empagliflozin	51	14
Tizanidine Hcl	Tizanidine Hcl	51	15
Diazepam	Diazepam	49	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	14
Montelukast Sodium	Montelukast Sodium	49	17
Carvedilol	Carvedilol	48	18
Finasteride	Finasteride	47	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	12
Fluoxetine Hcl	Fluoxetine Hcl	41	13
Atenolol	Atenolol	40	13
Ezetimibe	Ezetimibe	40	12
Aripiprazole	Aripiprazole	39	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	38	suppressed
Humalog Kwikpen U-100	Insulin Lispro	38	suppressed
Metformin Hcl Er	Metformin Hcl	37	14
Benztropine Mesylate	Benztropine Mesylate	36	suppressed
Glipizide	Glipizide	34	13
Xarelto	Rivaroxaban	34	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	suppressed
Synthroid	Levothyroxine Sodium	33	12
Spironolactone	Spironolactone	32	11
Potassium Chloride	Potassium Chloride	31	11
Celecoxib	Celecoxib	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Lovastatin	Lovastatin	29	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	27	11
Irbesartan	Irbesartan	27	suppressed
Methocarbamol	Methocarbamol	27	suppressed
Ozempic	Semaglutide	27	suppressed
Spiriva Respimat	Tiotropium Bromide	27	suppressed
Carisoprodol	Carisoprodol	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	26	suppressed
Estradiol	Estradiol	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Famotidine	Famotidine	24	suppressed
Prednisone	Prednisone	24	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Ibandronate Sodium	Ibandronate Sodium	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Clonazepam	Clonazepam	22	suppressed
Torsemide	Torsemide	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Buprenorphine	Buprenorphine	20	suppressed
Levofloxacin	Levofloxacin	20	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	16	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Cephalexin	Cephalexin	14	13
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	12
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Cystadane	Betaine	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Famciclovir	Famciclovir	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Naproxen	Naproxen	11	suppressed
Progesterone	Progesterone, Micronized	11	suppressed
Qulipta	Atogepant	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error